NUVB - Nuvation Bio Inc.
About Nuvation Bio Inc. (https://www.nuvationbio.com)
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation; NUV-569, a differentiated oral small molecule selective inhibitor of the Wee1 kinase for DNA damage repair; NUV-1182, an adenosine receptor inhibitor; and drug-drug conjugate (DDC) platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to anti-cancer warheads of existing drugs, as well as PARP inhibitor to address ER+ breast and ovarian cancer. The company was formerly known as RePharmation Inc. and changed its name to Nuvation Bio Inc. in April 2019. Nuvation Bio Inc. was founded in 2018 and is headquartered in New York, New York.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| David T. Hung | Founder, President, Chief Executive Officer & Chairman | 1958 | $1,202,100 USD |
| Philippe Sauvage | Chief Financial Officer & Principal Financial Officer | 1978 | $810,018 USD |
| Gary Hattersley | Chief Scientific Officer | 1967 | $805,803 USD |
| David Liu | Chief Medical Officer | 1970 | $677,151 USD |
| Colleen Sjogren | Chief Commercial Officer | 1971 | $615,841 USD |
| David C. Hanley | Chief Technical Operations Officer | 1970 | $586,040 USD |
| Kerry A. Wentworth | Chief Regulatory Officer | 1973 | – |
| Moses Makunje | Vice President of Finance and Principal Accounting & Financial Officer | 1979 | – |
| Robert DeVita | Vice President of Corporate Development & Investor Relations | – | – |
| Stacy Markel | Chief People Officer | 1965 | – |
| Stephen Dang | Chief Legal Officer & Corporate Secretary | – | – |